Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Bristol-Myers Opdivo,...

    Bristol-Myers Opdivo, Yervoy show promise in lung cancer trial

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-11-03T09:00:07+05:30  |  Updated On 16 Aug 2021 3:42 PM IST

    Bristol-Myers Squibb said its therapies when administered alongside two courses of chemotherapy demonstrated superior overall survival compared to chemotherapy alone in patients with advanced non-small cell lung cancer, the most common form of the disease.


    New Delhi: Bristol-Myers Squibb Co said on Tuesday an interim analysis of a late-stage trial testing a combination of its immuno-oncology drugs Opdivo and Yervoy met the main goal of extending the life of previously untreated lung cancer patients.


    Shares of the company rose 5% to $56 in premarket trading.


    The company said its therapies when administered alongside two courses of chemotherapy demonstrated superior overall survival compared to chemotherapy alone in patients with advanced non-small cell lung cancer, the most common form of the disease.


    Data presented at a medical meeting last month showed that about 40% of patients with advanced lung cancer on the Opdivo-Yervoy combination were alive after two years, outperforming chemotherapy as a first-line treatment.


    Read Also: Bristol Myers Squibb-Pfizer Alliance in collaboration with Fitbit to take on Apple Watch


    Opdivo and Yervoy compete with rival drugs from companies such as Merck & Co and Roche in several types of cancer.


    Merck's Keytruda dominates the highly lucrative market for newly diagnosed advanced lung cancer. Shares of the company fell 2.6% to $82.30 following the Bristol-Myers news.


    The interim analysis builds on the positive results the Opdivo-Yervoy combination has previously shown in melanoma and renal cell carcinoma, said Bristol-Myers, adding that it will present full data from the trial at an upcoming meeting.


    Read Also: Bristol-Myers CEO says Japan restrictive drug price policies risk diverting investment

    BMSBristolBristol-Myers SquibbcancercarcinomachemotherapyimmunotherapiesKeytrudalung cancerMerckMyersOpdivopharmapharma companypharma newsRocheYervoy
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok